Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marker Therapeutics, Inc. Director's Dealing 2011

Apr 5, 2011

35150_dirs_2011-04-05_e30dd8ba-2fc2-46d6-8101-1287d46739a1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2011-03-23

Reporting Person: CORIN DENIS (Director, President and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-03-23 Common Stock J 294118 $0.17 Acquired 2227868 Direct
2011-03-23 Common Stock S 160000 $0.12 Disposed 135300 Indirect

Footnotes

F1: These shares were issued in lieu of $50,000 worth of accrued and unpaid salary.